



News Release

Media Contact:

Rouzan Agadjanian

Phone: (949) 838-0154 x235

Email: rouzan@mccare.com

Major Improvement in Early Alzheimer's Disease Detection and Treatment Presented at the American Academy of Family Physicians Conference September 29 – October 1, 2005

Irvine, California, September 29, 2005—Medical Care Corporation (MCC), a health care company specializing in the early detection and management of Alzheimer's disease will demonstrate its new MCI Screen at the American Academy of Family Physicians conference in San Francisco September 29 through October 1.

The MCI Screen detects Mild Cognitive Impairment (MCI), a transition stage between the cognitive changes in normal aging and more severe impairment associated with dementia. Because MCI is the first stage of Alzheimer's disease, detecting it can allow physicians to intervene early to manage the disease effectively. According to a recent Mayo clinic study MCI patients have a 60% conversion rate to AD within six years.

The 10-minute, computer based exam allows specialists and primary care doctors to detect memory loss and early Alzheimer's disease with 97% accuracy. Since the test is noninvasive and easy to provide, it makes regular screening and early diagnosis possible for more people with memory concerns. Earlier detection allows better use of existing medications which can stave off the worst symptoms of AD for several years when started early.

Research confirming the accuracy and sensitivity of the screening tool published in the Proceedings of the Academy of Science (PNAS) in March of 2005. The study proved that by applying statistical modeling to the neuropsychological test battery used by the National Institute of Aging's Disease Research Centers, the accuracy for distinguishing normal aging from the mildest stage of Alzheimer's disease increased to 97%. This accuracy surpasses that of other more expensive and invasive diagnostic methods. The statistical model developed by a team lead by Dr. William Rodman Shankle, M.D., allows doctors to more accurately detect patients with mild cognitive impairment, a condition which precedes dementia caused by AD.

Early detection allows patients to start treatment at an earlier stage when current treatments are more effective. Data for the study was collected over the course of 10 years and included 471 subjects drawn from a university dementia research clinic and a community dementia clinic. A battery of neuropsychological tests, diagnostic laboratory testing and imaging studies were used to confirm the stage and diagnosis of each subject. A copy of the article is available on the company website: www.mccare.com

Not only is the screening approach accurate, it is also practical to use since clinic office staff can give it to the patient before a physician exam. The computerized system provides the physician with an instant report of the patients' memory function. Physicians can review the results, and pursue more diagnostic tests as needed. Patient care improves through the tracking feature which measures treatment response.

Over 10,000 patients have been evaluated with the MCI Screen by healthcare professionals in the USA during the past year. Additionally, three major Japanese healthcare companies adopted the technology earlier this year through licensing agreements with MCC.

The three Japanese companies include: Toyaku Corporation, Saint-Care Corporation, and Millenia Corporation. The rights to commercialize MCC's proprietary technology allow these firms to deliver a comprehensive range of dementia-care services, including: prevention, early detection, accurate diagnosis, and care management.

About Medical Care Corporation:

Medical Care Corporation (MCC) specializes in medical technologies that enable healthcare providers to deliver improved levels of care in the dementia field. MCC's electronic Dementia Care System gathers, organizes, and synthesizes patient and treatment information so that professionals can offer a "best-practice" level of dementia care. The MCI Screen, the centerpiece of MCC's proprietary technologies, is the most sensitive tool available for detecting early stage memory loss. This highly sensitive test allows healthcare providers to identify and manage Alzheimer's disease and related disorders at the earliest stages and use currently approved treatment modalities more effectively. The company is also a leader in communicating the value of prevention and early detection to patients and caregivers through its website and educational materials. More information about the company is available at two websites: Health care providers: www.mccare.com; Patients and Caregivers: www.preventad.com